{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:17:37Z","timestamp":1792646257198,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1-R01-CA214146-01"],"award-info":[{"award-number":["1-R01-CA214146-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1-R35-NS07211-01"],"award-info":[{"award-number":["1-R35-NS07211-01"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000913","name":"James S. McDonnell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000913","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>One of the clinical hallmarks of low-grade gliomas (LGGs) arising in children with the neurofibromatosis type 1 (NF1) cancer predisposition syndrome is significant clinical variability with respect to tumor growth, associated neurologic deficits, and response to therapy. Numerous factors could contribute to this clinical heterogeneity, including the tumor cell of origin, the specific germline NF1 gene mutation, and the coexistence of additional genomic alterations. Since human specimens are rarely acquired, and have proven difficult to maintain in vitro or as xenografts in vivo, we have developed a series of Nf1 mutant optic glioma mouse strains representing each of these contributing factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Optic glioma stem cells (o-GSCs) were generated from this collection of Nf1 genetically engineered mice, and analyzed for their intrinsic growth properties, as well as the production of chemokines that could differentially attract T cells and microglia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The observed differences in Nf1 optic glioma growth are not the result of cell autonomous growth properties of o-GSCs, but rather the unique patterns of o-GSC chemokine expression, which differentially attract T cells and microglia. This immune profile collectively dictates the levels of chemokine C-C ligand 5 (Ccl5) expression, the key stromal factor that drives murine Nf1 optic glioma growth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings reveal that genetic and genomic alterations create murine LGG biological heterogeneity through the differential recruitment of T cells and microglia by o-GSC\u2013produced chemokines, which ultimately determine the expression of stromal factors that drive tumor growth.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noz080","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T15:13:29Z","timestamp":1556723609000},"page":"1250-1262","source":"Crossref","is-referenced-by-count":103,"title":["Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell\u2013specific chemokine recruitment of T cells and microglia"],"prefix":"10.1093","volume":"21","author":[{"given":"Xiaofan","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Gutmann","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"issue":"5","key":"2019100905384024300_CIT0001","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/0883073813476141","article-title":"Pilocytic astrocytoma: a disease with evolving molecular heterogeneity","volume":"28","author":"Sadighi","year":"2013","journal-title":"J Child Neurol."},{"issue":"9","key":"2019100905384024300_CIT0002","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/NEN.0b013e3182656ef8","article-title":"BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper","volume":"71","author":"Rodriguez","year":"2012","journal-title":"J Neuropathol Exp Neurol."},{"issue":"21","key":"2019100905384024300_CIT0003","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","article-title":"Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer Res."},{"issue":"8","key":"2019100905384024300_CIT0004","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat Genet."},{"issue":"1","key":"2019100905384024300_CIT0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-3476(94)70122-9","article-title":"Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study","volume":"125","author":"Listernick","year":"1994","journal-title":"J Pediatr."},{"issue":"1","key":"2019100905384024300_CIT0006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0883073817739509","article-title":"Optic pathway gliomas in neurofibromatosis type 1","volume":"33","author":"Campen","year":"2018","journal-title":"J Child Neurol."},{"issue":"11","key":"2019100905384024300_CIT0007","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1158\/1078-0432.CCR-10-3349","article-title":"BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model","volume":"17","author":"Raabe","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"24","key":"2019100905384024300_CIT0008","first-page":"8573","article-title":"Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity","volume":"63","author":"Bajenaru","year":"2003","journal-title":"Cancer Res."},{"issue":"5","key":"2019100905384024300_CIT0009","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/neuonc\/nou287","article-title":"The impact of coexisting genetic mutations on murine optic glioma biology","volume":"17","author":"Kaul","year":"2015","journal-title":"Neuro Oncol."},{"issue":"29","key":"2019100905384024300_CIT0010","doi-asserted-by":"crossref","first-page":"47206","DOI":"10.18632\/oncotarget.17589","article-title":"The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation","volume":"8","author":"Solga","year":"2017","journal-title":"Oncotarget."},{"issue":"9","key":"2019100905384024300_CIT0011","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/hmg\/ddw039","article-title":"NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1","volume":"25","author":"Toonen","year":"2016","journal-title":"Hum Mol Genet."},{"issue":"4","key":"2019100905384024300_CIT0012","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1365-2990.2000.00258.x","article-title":"Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas","volume":"26","author":"Gutmann","year":"2000","journal-title":"Neuropathol Appl Neurobiol."},{"key":"2019100905384024300_CIT0013","doi-asserted-by":"crossref","first-page":"e07780","DOI":"10.7554\/eLife.07780","article-title":"Loss of neurofibromin Ras-GAP activity enhances the formation of cardiac blood islands in murine embryos","volume":"4","author":"Yzaguirre","year":"2015","journal-title":"Elife"},{"issue":"10","key":"2019100905384024300_CIT0014","doi-asserted-by":"crossref","first-page":"e13693","DOI":"10.1371\/journal.pone.0013693","article-title":"Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice","volume":"5","author":"Saederup","year":"2010","journal-title":"PLoS One."},{"issue":"11","key":"2019100905384024300_CIT0015","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.celrep.2015.02.041","article-title":"Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties","volume":"10","author":"Chen","year":"2015","journal-title":"Cell Rep."},{"issue":"7-8","key":"2019100905384024300_CIT0016","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1101\/gad.310797.117","article-title":"Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth","volume":"32","author":"Pan","year":"2018","journal-title":"Genes Dev."},{"issue":"5","key":"2019100905384024300_CIT0017","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/0008-5472.CAN-07-5916","article-title":"Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma","volume":"68","author":"Hegedus","year":"2008","journal-title":"Cancer Res."},{"issue":"32","key":"2019100905384024300_CIT0018","doi-asserted-by":"crossref","first-page":"52474","DOI":"10.18632\/oncotarget.17193","article-title":"Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN\/PI3K-regulated glioma transcriptional signature","volume":"8","author":"Pan","year":"2017","journal-title":"Oncotarget."},{"issue":"9","key":"2019100905384024300_CIT0019","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/hmg\/ddm059","article-title":"Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth","volume":"16","author":"Daginakatte","year":"2007","journal-title":"Hum Mol Genet."},{"issue":"2","key":"2019100905384024300_CIT0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.23813","article-title":"Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation","volume":"73","author":"Pong","year":"2013","journal-title":"Ann Neurol."},{"issue":"10","key":"2019100905384024300_CIT0021","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.neo.2015.10.002","article-title":"RNA sequencing of tumor-associated microglia reveals Ccl5 as a stromal chemokine critical for neurofibromatosis-1 glioma growth","volume":"17","author":"Solga","year":"2015","journal-title":"Neoplasia."},{"issue":"12","key":"2019100905384024300_CIT0022","doi-asserted-by":"crossref","first-page":"E1738","DOI":"10.1073\/pnas.1525528113","article-title":"New tools for studying microglia in the mouse and human CNS","volume":"113","author":"Bennett","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"36","key":"2019100905384024300_CIT0023","doi-asserted-by":"crossref","first-page":"11929","DOI":"10.1523\/JNEUROSCI.1860-14.2014","article-title":"An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex","volume":"34","author":"Zhang","year":"2014","journal-title":"J Neurosci."},{"issue":"12","key":"2019100905384024300_CIT0024","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.it.2013.03.004","article-title":"Immunological genome project and systems immunology","volume":"34","author":"Shay","year":"2013","journal-title":"Trends Immunol."},{"issue":"9","key":"2019100905384024300_CIT0025","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1167\/iovs.08-3357","article-title":"Regulation of dynamic behavior of retinal microglia by CX3CR1 signaling","volume":"50","author":"Liang","year":"2009","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"1","key":"2019100905384024300_CIT0026","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/joim.12240","article-title":"The challenge of intratumour heterogeneity in precision medicine","volume":"276","author":"Seoane","year":"2014","journal-title":"J Intern Med."},{"issue":"1","key":"2019100905384024300_CIT0027","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat Neurosci."},{"issue":"3","key":"2019100905384024300_CIT0028","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell."},{"issue":"10","key":"2019100905384024300_CIT0029","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med."},{"issue":"17","key":"2019100905384024300_CIT0030","doi-asserted-by":"crossref","first-page":"15077","DOI":"10.18632\/oncotarget.3730","article-title":"Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis","volume":"6","author":"Feng","year":"2015","journal-title":"Oncotarget."},{"issue":"2","key":"2019100905384024300_CIT0031","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/neuonc\/nou324","article-title":"Glioma-derived versican promotes tumor expansion via glioma-associated microglial\/macrophages Toll-like receptor 2 signaling","volume":"17","author":"Hu","year":"2015","journal-title":"Neuro Oncol."},{"issue":"11","key":"2019100905384024300_CIT0032","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/neuonc\/not115","article-title":"Toll-like receptor 2 mediates microglia\/brain macrophage MT1-MMP expression and glioma expansion","volume":"15","author":"Vinnakota","year":"2013","journal-title":"Neuro Oncol."},{"issue":"14","key":"2019100905384024300_CIT0033","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-11-0127","article-title":"Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas","volume":"17","author":"Jacob","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2019100905384024300_CIT0034","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1158\/0008-5472.CAN-17-2433","article-title":"Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma","volume":"78","author":"Sadahiro","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"2019100905384024300_CIT0035","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12974-017-0993-4","article-title":"EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment","volume":"14","author":"Yin","year":"2017","journal-title":"J Neuroinflammation."},{"issue":"8","key":"2019100905384024300_CIT0036","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1101\/gad.294991.116","article-title":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","volume":"31","author":"Amankulor","year":"2017","journal-title":"Genes Dev."},{"issue":"1","key":"2019100905384024300_CIT0037","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bpa.12646","article-title":"Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia","volume":"29","author":"Rodriguez","year":"2019","journal-title":"Brain Pathol."},{"issue":"1","key":"2019100905384024300_CIT0038","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40478-016-0361-0","article-title":"Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation","volume":"4","author":"Orillac","year":"2016","journal-title":"Acta Neuropathol Commun."},{"issue":"2","key":"2019100905384024300_CIT0039","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00401-018-1837-8","article-title":"Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A\/B and ATRX alterations","volume":"136","author":"Reinhardt","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"7","key":"2019100905384024300_CIT0040","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/NEN.0000000000000213","article-title":"KIAA1549: BRAF gene fusion and FGFR1 hotspot mutations are prognostic factors in pilocytic astrocytomas","volume":"74","author":"Becker","year":"2015","journal-title":"J Neuropathol Exp Neurol."},{"issue":"10","key":"2019100905384024300_CIT0041","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1038\/bjc.2014.162","article-title":"Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma","volume":"110","author":"Han","year":"2014","journal-title":"Br J Cancer."},{"key":"2019100905384024300_CIT0042","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clineuro.2018.02.044","article-title":"Correlation and clinical significance of LC3, CD68+ microglia, CD4+ T lymphocytes, and CD8+ T lymphocytes in gliomas","volume":"168","author":"Zhang","year":"2018","journal-title":"Clin Neurol Neurosurg."},{"issue":"3","key":"2019100905384024300_CIT0043","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3171\/2011.4.JNS101172","article-title":"Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology","volume":"115","author":"Yang","year":"2011","journal-title":"J Neurosurg."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noz080\/28797528\/noz080.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/21\/10\/1250\/30122479\/noz080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/21\/10\/1250\/30122479\/noz080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T05:39:13Z","timestamp":1570599553000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/21\/10\/1250\/5485427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,5,3]]},"published-print":{"date-parts":[[2019,10,9]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noz080","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,5,3]]}}}